United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - phenylpropanolamine hydrochloride - oral solution - 5mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

United States - English - NLM (National Library of Medicine)

wockhardt usa, inc. - triprolidine hydrochloride (unii: yan7r5l890) (triprolidine - unii:2l8t9s52qm), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), codeine phosphate (unii: gsl05y1mn6) (codeine - unii:q830pw7520) - syrup - 1.25 mg in 5 ml - pseudodine™ c cough syrup is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. pseudodine™ c cough syrup is contraindicated under the following conditions: this drug should not be used in newborn or premature infants. antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (mao) inhibitor therapy (see precautions, drug interactions ). like other medications containing a narcotic, pseudodine™ c cough syrup is controlled by the drug enforcement administration. it is classified under schedule v. codeine can produce drug dependence of the morphine typ

Ireland - English - HPRA (Health Products Regulatory Authority)

pegasus laboratories ireland limited - phenylpropanolamine hydrochloride - chewable tablet - 15 mg/tablet - phenylpropanolamin

Ireland - English - HPRA (Health Products Regulatory Authority)

pegasus laboratories ireland limited - phenylpropanolamine hydrochloride - chewable tablet - 50 mg/tablet - phenylpropanolamin

Ireland - English - HPRA (Health Products Regulatory Authority)

dechra regulatory b.v. - phenylpropanolamine hydrochloride - syrup - 40 milligram(s)/millilitre - phenylpropanolamin

Ireland - English - HPRA (Health Products Regulatory Authority)

fatro s.p.a. - phenylpropanolamine hydrochloride - syrup - 40 milligram(s)/millilitre - phenylpropanolamin

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra ltd - phenylpropanolamine hydrochloride - oral solution/suspension - phenylpropanolamine hydrochloride ammonium-quaternary active 50.0 mg/ml - genitourinary system

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules, usp are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules, usp. the long-term effects of terazosin capsules, usp on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules, usp are also indicated for the treatment of hypertension. terazosin capsules, usp can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.